To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
- Registration Number
- NCT02029209
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Brief Summary
1. To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the phase II study of anlotinib in patients with advanced non-small cell lung cancer.
2. To clarify the meaning of peripheral markers and blood perfusion parameters in vivo tumor in predicting the effect of anti-angiogenic therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 110
- Pathology diagnosed with advanced NSCLC with measurable lesions;
- Have failed for 2 lines of chemotherapy; 3.18-70 years,ECOG PS:0-2,life expectancy of more than 3 months;
4.Other cytotoxic drugs,radiation therapy,or surgery≥4 weeks; 5.Main organs function is normal; 6.Women of childbearing age should take contraceptive measures during the study and within 6 months after end.
- SCLC(including mixed with NSCLC);
- The central cavity of Squamous cell carcinoma and hemoptysis with NSCLC;
- Patients failed to use the anti-tumor angiogenesis therapy;
- Patients have many influence factors toward oral medications ;
- Brain metastases patients accompanied by symptoms or symptom control for less than two months;
- Patients with severe and failed to controlled diseases,including: suboptimal blood pressure control;suffering from myocardial ischemia or above grade I myocardial infarction, arrhythmias and Class I heart failure;activity or failure to control severe infections;liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis;poorly controlled diabetes (FBG>10mmol/L);urine protein≥++,etc.
- Patients failed to heal wounds or fractures for Long-term;
- 4 weeks before enrollment, patients appeared NCI CTC AE grading >1 pulmonary hemorrhage; 4 weeks before enrollment, patients who appeared NCI CTC AE grade> 2 had other parts of the bleeding; patients have a tendency to bleed (e.g active peptic ulcer) or are receiving thrombolytic or anticoagulant therapy such as Warfarin, heparin or its analogues;
- Patients occurred venous thromboembolic events within 6 months;
- Patients who have HIV-positive or organ transplantation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Capsule Placebo Capsule Placebo capsule QD orally and it should be continued until disease progression or patients withdrawal of consent Anlotinib Anlotinib Anlotinib QD orally and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
- Primary Outcome Measures
Name Time Method Number of circulating endothelial cell subsets（ total CECs 、 aCECs、apopCECs, etc.) Different time points before and after treatment of anlotinib,an expected average of 3 weeks To detect number of circulating endothelial cell subsets（ total CECs 、aCECs、apopCECs, etc.) by Flow Cytometry;
The strength of intratumoral blood perfusion index (BV, BF, PS and MTT) . Different time points before and after treatment of anlotinib,an expected average of 3 weeks To detect the strength of intratumoral blood perfusion index(BV, BF, PS and MTT) by CT perfusion imaging.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital .
🇨🇳Tianjin, Tianjin, China